Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands
Luuk van Esveld, Juul M. Cox, T. Martijn Kuijper, Tessa M. Bosch, A. Weel
Topics & Concepts
MedicineDiscontinuationTaperingRheumatoid arthritisQuality-adjusted life yearCost-effectiveness analysisMarginal costInternal medicineCost effectivenessRisk analysis (engineering)EconomicsComputer scienceComputer graphics (images)MicroeconomicsRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical MethodsPharmaceutical Economics and Policy